Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a non-infectious recombinant vaccine composed of virus-like particles (VLPs) derived from the L1 capsid proteins of Human Papillomavirus (HPV) types 6, 11, 16, and 18. It functions by stimulating the immune system to produce specific antibodies against these HPV types, thereby preventing infection and subsequent HPV-related diseases. The vaccine is indicated for the prevention of cervical cancer, vulvar and vaginal precancer and cancers, precancerous lesions, and genital warts associated with HPV types 6, 11, 16, and 18.
- Brand names
- Gardasil
- Other names
- Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccinequadrivalent HPV (type 6, 11, 16 and 18) L1 virus-like particle vaccine
02
Targets
HPV11 L1HPV18 L1HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)HPV16 (Human papillomavirus type 16)
Beyond the preview
Go deeper on quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine.